作者:Paul W. Finn、Morwena Bandara、Chris Butcher、Angela Finn、Ruth Hollinshead、Nagma Khan、Norman Law、Sreenivasa Murthy、Rosario Romero、Clare Watkins、Victor Andrianov、Rasma M. Bokaldere、Klara Dikovska、Vija Gailite、Einars Loza、Irina Piskunova、Igor Starchenkov、Maxim Vorona、Ivars Kalvinsh
DOI:10.1002/hlca.200590129
日期:2005.7
Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative
抑制酶组蛋白脱乙酰基酶(HDAC)成为一种新型的癌症治疗方法。合成了一系列新颖的磺酰胺衍生物,并对其抑制人HDAC的能力进行了评估。鉴定出有效酶抑制剂的化合物,IC 50相对于从HeLa细胞提取物中获得的酶而言,其在低纳摩尔浓度范围内的值较低,并且对细胞培养具有抗增殖作用。该系列的结构-活动关系的广泛表征确定了活动的关键要求。这些包括磺酰胺键的方向和中心苯环上的取代模式。芳族头基和磺酰胺官能团之间的烷基间隔基也影响了HDAC的抑制活性。其中一种化合物m 11.1(也称为PXD101)已进入实体瘤和血液系统恶性肿瘤的临床试验。